A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia (NCT05304377)
A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TKIs.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Cancer Center — New York, New York
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (45 Sites)
Showing the first 25 of 45 sites.
- Memorial Sloan Kettering Cancer Center — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Oregon Health & Science University-Knight Cardiovascular Institute — Portland, Oregon
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Royal Adelaide Hospital — Adelaide,
- UZ Gent — Ghent,
- UZ Leuven — Leuven,
- CHU Liege — Liège,
- University Health Network (UHN) - Princess Margaret Cancer Centre — Toronto, Ontario
- CHU Amiens Picardie Site Sud — Amiens,
- Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest — Bordeaux,
- CHRU de Lille - Hopital Calmette-Boulevard du Pr Leclercq CHRU Lille — Lille,
- Centre Hospitalier Universitaire (CHU) De Limoges Hopital Dupuytren — Limoges,
- Centre Leon Berard — Lyon,
- Centre Hospitalier Lyon Sud — Pierre-Bénite,
- Uniklinik RWTH Aachen Medizinische — Aachen,
- Charite Campus Virchow — Berlin,
- Klinikum der Goethe Universitat — Frankfurt,
- Universitaetsklinikum Des Saarlandes Und Medizinische Fakultaet Der Universitaet Des Saarlandes — Homburg,
- Universitaetsklinikum Jena — Jena,
- Medizinische Universitatsklinik Mannheim der Universitat Heidelberg — Mannheim,
- Universitaetsmedizin Rostock — Rostock,
- Semmelweis Egyetem, Belgyogyaszati es Onkologiai Klinika — Budapest,
- Pecsi Tudomanyegyetem Klinikai Kozpont (University of Pecs, Clinical Centre) — Pécs,
- Hadassah Medical Center — Jerusalem,
📞 Contact the Study Coordinator
Phone: (707) 799-3272
Email: ELVN-001-101@enliventherapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Myeloid Leukemia
- Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population — Houston, Texas
- Selumetinib and Azacitidine in High Risk Chronic Blood Cancers — Chicago, Illinois
- Study of Olverembatinib (HQP1351) in Patients With CP-CML — Houston, Texas
- Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase — Houston, Texas
- Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. — Houston, Texas
Explore by condition: All Chronic Myeloid Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.